Skip to main content
ABUS logo

ABUS · Arbutus Biopharma Corp

Track ABUS — free
$4.02 -0.05 (-1.23%) At close · Nov 20
Market Cap
$616.24M
Shares
153.29M
Volume · Nov 20 2.99M Avg daily vol (3M) 5.19M

Price & Indicators

 

Key stats

Close
$4.02
Fri 20 Nov
Open
$4.01
Fri 20 Nov
Average volume, 30 days
2.6M
shares a session
Short interest
19.9M
13.0% of shares · 9.1 days to cover
Day range
$3.97$4.09
Open $4.01 Close $4.02
52-week closing range
$3.66$5.22
Close $4.02 23.0% under the high
Short volume, last session
54%
Last earnings
Nov 21, 2024
Latest filing
10-Q · Nov 10
Price history
Jan 2020 to Nov 2026

Up next

call held Nov 21, 2024

Latest documents

2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA lifts clinical hold on AB-101 program

Arbutus Biopharma Corporation said the FDA lifted its clinical hold on AB-101’s IND application in October 2026, allowing additional clinical development in the United States.

Revenue $299K ▼ 43.5% Net income $59.12M Diluted EPS $0.30
Read from the MD&A section
2 source passages
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. In October 2026, the United States Food and Drug Administration (FDA) lifted its clinical hold on the Investigational New Drug (IND) application for AB-101, our proprietary oral PD-L1 inhibitor for the treatment of cHBV infection. We are now able to engage in additional clinical development for AB-101 in the United States and are evaluating next steps for the continued development of AB-101. Open the document at this passage
Nov 10
Current report 8-K
Net income of $59.1 million; $230 million returned to shareholders

Arbutus Biopharma reported net income of $59.1 million for the quarter ended September 30, 2026, compared with a net loss of $7.7 million a year earlier. It completed a tender offer in early October 2026, buying 46 million shares at $5.00 per share and returning $230 million to shareholders. Cash, cash equivalents and marketable securities were $337.5 million as of September 30, 2026.

Financial results
4 source passages
For the quarter ended September 30, 2026, the Company's net income was $59.1 million, or net income of $0.30 per basic and diluted common share, as compared to a net loss of $7.7 million, or a net loss of $0.04 per basic and diluted common share, for the quarter ended September 30, 2025. In early October 2026, the Company successfully completed its modified "Dutch Auction" tender offer (the "Offer"), returning $230 million of capital to shareholders. In the Offer, the Company purchased 46 million common shares for cancellation at $5.00 per share, representing approximately 23% of its issued and outstanding common shares as of September 29, 2026. As of September 30, 2026, the Company had cash, cash equivalents and investments in marketable securities of $337.5 million compared to $91.5 million as of December 31, 2025. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 20
FDA Lifts Clinical Hold on AB-101 IND Application

The FDA notified the company that the clinical hold on the IND application for AB-101, its oral PD-L1 inhibitor, has been removed, allowing additional clinical development in the United States. Arbutus is evaluating next steps for AB-101's continued development.

Other events
3 source passages
the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company’s oral PD-L1 inhibitor the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States Arbutus is evaluating next steps for the continued development of AB-101. Open the document at this passage
Oct 1
Tender offer SC TO-I/A
Tender offer

Arbutus Biopharma Corporation accepted 46,000,000 Shares at US$5.00 per Share, an aggregate US$230 million purchase price representing approximately 23 percent of its outstanding Shares; settlement is expected on or about October 5, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$181.49M
Trailing 12 months
Net income (TTM)
$219.91M
Trailing 12 months
Revenue growth YoY
-43.5%
Year over year
Operating margin
81.1%
Trailing 12 months
P / E (TTM)
3.6
Trailing earnings · reciprocal yield 28.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$264.19M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.1%
Year over year · more shares
Price change (1Y)
-4.3%
Trailing year
Short interest
13.0%
Latest settlement · 9.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −8%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 23%
mid-range
Momentum
relative strength
Weak
1-month return −4%
trailing
6-month return −6%
trailing
YTD return −16%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+23% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.97% of shares out · ▼ -19.0% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
218 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth +128%
Y/Y
EPS growth +55%
Y/Y
Free cash flow $-39.6M
Valuation P/E 3.6
below peers
Buyback $230.0M
authorized
Balance sheet $18.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −30%
past year
ATR 4.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 12, 2026
Capital return to shareholders through repurchases of common sha · commencing in Q3 2026 up to $230M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
23% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+23% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.97% of shares out · ▼ -19.0% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
218 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $4 · 23% Range high $5
vs 200-day avg -10% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities $337.5M As of September 30, 2026 —
common shares issued and outstanding 199.3M As of September 30, 2026 —
Options granted during period 13,400 the three months ended September 30, 2026 filing —
stock options and unvested restricted stock units outstanding 6.4M As of September 30, 2026 —
Weighted average exercise price $4.41 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABUS
Arbutus Biopharma Corp
this stock
$616.24M -16.4% +128.2% 3.6 13.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
218
% held
86.5%
Net QoQ
-8.0M sh
Top holder
MORGAN STANLEY
Held Float
View
Held by Funds
Fund positions
144
View
Short & Settlement
Short Interest Falling
Shares short
19.9M
Days to cover
9.1d
Change
-4.7M sh
View
Short Volume
Short vol %
54%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$5.3K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$14.1M
Net income (FY)
$-33.5M
EPS diluted
$-0.17
View
Buybacks
Authorized
$230.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 12, 2026
This year
24

Arbutus Biopharma Corporation posted an updated corporate presentation on November 12, 2026.

View
Proposed Sales
Value
$804.9K
Shares
246.9K
Filed
Apr 21, 2025
View
Exempt Offerings
Offering
$15.0M
Filed
Dec 30, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 21, 2024
View
Investor Relations
Latest news
Arbutus Reports Third Quarter 202…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
ABUS -1.7% -4.3% -5.6% -4.5% -16.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +6.9% +4.9% +3.6% +4.2% -17.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$230.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 221 filings 200 filers Visit website Investor relations